<SEC-DOCUMENT>0001171843-20-001589.txt : 20200310
<SEC-HEADER>0001171843-20-001589.hdr.sgml : 20200310
<ACCEPTANCE-DATETIME>20200310092643
ACCESSION NUMBER:		0001171843-20-001589
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20200304
ITEM INFORMATION:		Termination of a Material Definitive Agreement
FILED AS OF DATE:		20200310
DATE AS OF CHANGE:		20200310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		20700138

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k_031020.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><FONT STYLE="font-size: 14pt"><B>FORM 8-K</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><B>CURRENT REPORT</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>PURSUANT TO SECTION 13 OR 15(d)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>Date of Report (Date of earliest event reported): March 4, 2020</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 18pt; text-align: center; text-indent: 0.2in; margin: 0"><B>BioCryst Pharmaceuticals, Inc.</B></P>

<P STYLE="font-size: 10pt; margin: 0; text-align: center"><FONT STYLE="font-weight: normal"><I>(Exact Name of Registrant as Specified
in Charter)</I></FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; text-align: center; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center; font-weight: bold"><FONT STYLE="font-size: 10pt"><B>000-23186</B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>62-1413174</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(State or Other Jurisdiction</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(Commission</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>(IRS Employer</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>of Incorporation)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>File Number)</I></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><I>Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>4505 Emperor Blvd., Suite 200<BR>
Durham, North Carolina 27703</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Address of Principal Executive Offices)</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><B>(919) 859-1302</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Registrant&rsquo;s telephone number, including area code)</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">________________________________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>(Former Name or Former Address, if Changed Since Last Report)</I></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2
below):</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"><P STYLE="text-align: center; font-size: 10pt; color: rgb(0, 0, 0)"><FONT STYLE="font-style: normal; font-weight: 400; text-decoration: initial; color: (error); text-transform: none">&#9744;</FONT></P>


</TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"><P STYLE="text-align: center; font-size: 10pt; color: rgb(0, 0, 0)"><FONT STYLE="font-style: normal; font-weight: 400; text-decoration: initial; color: (error); text-transform: none">&#9744;</FONT></P>


</TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"><P STYLE="text-align: center; font-size: 10pt; color: rgb(0, 0, 0)"><FONT STYLE="font-style: normal; font-weight: 400; text-decoration: initial; color: (error); text-transform: none">&#9744;</FONT></P>


</TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;210.14d-2(b))</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"><P STYLE="text-align: center; font-size: 10pt; color: rgb(0, 0, 0)"><FONT STYLE="font-style: normal; font-weight: 400; text-decoration: initial; color: (error); text-transform: none">&#9744;</FONT></P>


</TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 32%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 43%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>BCRX</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Nasdaq Global Select Market</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0">Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &sect;240.12b-2).</P>

<P STYLE="font-size: 10pt; text-align: right; text-indent: -0.5in; margin: 6pt 0 12pt 0.5in">Emerging growth company&#9;&#9744;</P>

<P STYLE="font-size: 10pt; text-indent: 0in; margin: 0 0 12pt">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt; text-align: left"><B>Item&nbsp;1.02 Termination of a Material Definitive Agreement</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">On March 4, 2020, the International Court of Arbitration of the International
Chamber of Commerce (&ldquo;ICC Tribunal&rdquo;) delivered a Partial Arbitration Award (the &ldquo;Partial Arbitration Award&rdquo;)
in the arbitration matter between BioCryst Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) and Seqirus UK Limited (&ldquo;Seqirus&rdquo;)
with respect to the License Agreement dated June 16, 2015 between the Company and Seqirus (the &ldquo;SUL Agreement&rdquo;) relating
to the commercialization of peramivir (RAPIVAB/ALPIVAB) worldwide (excluding Japan, Taiwan, Korea, and Israel, the &ldquo;Territory&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">In the Partial Arbitration Award, the ICC Tribunal found that,
during the term,  Seqirus materially breached and abandoned its core duties to the Company under the Diligent Efforts (as
defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a
declaratory judgment in favor of the Company terminating the SUL Agreement and restoring all rights to peramivir to the
Company as of March 17, 2020 (or such other date as the parties agree). The ICC Tribunal also awarded the Company its
attorneys&rsquo; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by the Company
in the arbitration. Finally, the ICC Tribunal found that Seqirus breached the SUL Agreement by failing to pay the milestone
payment due to the Company within 30 days of the approval of peramivir for adult use in the European Union and awarded the
Company $5.0 million (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating
to the award of attorneys&rsquo; fees and for any dispute relating to the return to the Company of all rights to peramivir in
the Territory.&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.2in; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 51%; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: March 10, 2020</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%; text-align: left"><FONT STYLE="font-size: 10pt"><B>BioCryst Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">By:</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><U>/s/ Alane Barnes&#9;</U></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Alane Barnes</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 51.9pt; text-align: left; text-indent: -51.9pt"><FONT STYLE="font-size: 10pt">Senior Vice President
and Chief Legal Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
